SAFETY DATA SHEET

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Celecoxib Capsules

Product Code(s) CELECOXIB CAPSULES
Trade Name: CELEBREX, CELEBRA, CELEBRA FEM, CELEBRA MAX, SOLEXA, CELORA, ACLARIX, ACLAREX, ARTILOG, ARTRID, CELECOX, VALDYNE, VALDYN, CAPSURE, CELATRIT, KUDEQ, SYRIBEX, DICOXIBE, IGEF
Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as Non-steroidal, anti-inflammatory drug (NSAID)

1.3. Details of the supplier of the safety data sheet

Pfizer Inc
66 Hudson Boulevard East
New York, New York 10001
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Emergency Telephone - 1-212-573-2222
Hours of Operations - 24 Hours

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification

Reproductive toxicity	Category 1B - (H360D)
Specific target organ toxicity (repeated exposure)	Category 2 - (H373)
Acute aquatic toxicity	Category 3 - (H402)
Chronic aquatic toxicity	Category 1 - (H410)

2.2. Label elements

Signal word Danger

Hazard statements
H360D - May damage the unborn child
H373 - May cause damage to organs through prolonged or repeated exposure: gastrointestinal system, kidneys
H402 - Harmful to aquatic life
H410 - Very toxic to aquatic life with long lasting effects

Precautionary Statements P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations



2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Celecoxib (CAS #: 169590-42-5)	74		Not Listed	STOT RE 2 (H373) Aquatic Chronic 1 (H410) Repr. 1B (H360D)	Not Listed	Chronic M=1	No data available
Sodium lauryl sulfate (CAS #: 151-21-3)	1 - 5		205-788-1	Acute Tox.4 (H302) Skin Irrit.2 (H315) Eye Dam.1 (H318) Aquatic Chronic 3 (H412)	10-<20% Eye Irrit 2 >=20% Eye Dam 1	No data available	No data available
Magnesium Stearate (CAS #: 557-04-0)	*	-	209-150-3	Not classified as hazardous	Not Listed	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH	EC No	Classification	Specific	M-Factor	M-Factor

		Registration Number		according to Regulation (EC) No. 1272/2008 [CLP]	concentration limit (SCL)		(long-term)
Lactose NF, monohydrate (CAS #: 64044-51-5)	*	-	Not Listed	Not classified as hazardous	Not Listed	No data available	No data available
Povidone (CAS #: 9003-39-8)	*	-	Not Listed	Not classified as hazardous	Not Listed	No data available	No data available
Croscarmellose sodium (CAS #: 74811-65-7)	*	-	Not Listed	Not classified as hazardous	Not Listed	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Celecoxib 169590-42-5	>2000	No data available	No data available	No data available	No data available
Sodium lauryl sulfate 151-21-3	1200	>2000	0.975	No data available	No data available
Povidone 9003-39-8	100000	No data available	No data available	No data available	No data available
Magnesium Stearate 557-04-0	> 2000	No data available	>2	No data available	No data available

Additional information

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation

Remove to fresh air. Seek immediate medical attention/advice.

Eye contact

Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.

Skin contact

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians	None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media	Dry chemical, CO2, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical	Fine particles (such as dust and mists) may fuel fires/explosions.
Hazardous combustion products	Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for fire-fighters	Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
For emergency responders	Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment	Prevent further leakage or spillage if safe to do so.
Methods for cleaning up	Avoid use of a filtered vacuum to clean spills of dry solids. Contain the source of the spill or leak. Clean spill area thoroughly. Collect spilled material by a method that controls dust generation.
Prevention of secondary hazards	Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections	See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken,. avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or

other equivalent controls. Refer to Section 12 - Ecological Information, for information on potential effects on the environment.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits
Refer to available public information for specific member state Occupational Exposure Limits.

Celecoxib
Pfizer OEL TWA-8 Hr: 1000 µg/m³

Sodium lauryl sulfate
Pfizer OEL TWA-8 Hr: 300 µg/m³

Povidone

Russia	MAC: 10 mg/m³

Magnesium Stearate

ACGIH TLV	10 mg/m³ 3 mg/m³
Ireland	10 mg/m³ STEL: 30 mg/m³
Spain	10 mg/m³

8.2. Exposure controls

Engineering controls General room ventilation is adequate unless the process generates dust, mist or fumes. Engineering controls should be used as the primary means to control exposures. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental exposure controls No information available.

Personal protective equipment Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10

or international equivalent.)

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Capsule
Color	White and Blue; gold or Green
Odor	No information available.
Odor threshold	No information available
Molecular formula	Mixture
Molecular weight	Mixture

Property	**Values**
pH	No data available
Melting point / freezing point	No data available
Boiling point / boiling range	
Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

Partition Coefficient: (Method, pH, Endpoint, Value)
Celecoxib
Measured Log P 3.53
Sodium lauryl sulfate
Measured Log P 0.83

9.2. Other information
No information available

9.2.1. Information with regard to physical hazard classes
No information available

9.2.2. Other safety characteristics
No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:	The information included in this section describes the potential hazards of the individual ingredients
Short term	May cause minimal eye irritation (based on animal data). May cause allergic reaction in sensitive individuals.
Long Term:	Repeat-dose studies in animals have shown a potential to cause adverse effects on gastrointestinal system, kidneys and the developing fetus.
Known Clinical Effects:	Ingestion of this material may cause effects similar to those seen in clinical use including gastrointestinal effects such as nausea, pain, heartburn, bleeding, ulceration, and perforation. Serious allergic reactions, including anaphylaxis, have been reported. Clinical use of this drug has caused swelling of face/extremities, hives, redness and swelling of the skin (urticaria), skin rash, chills, yellowing of skin and eyes, headache, dizziness, vomiting, diarrhea, insomnia, increase in blood pressure (hypertension), respiratory infection, chest pain, heart attack (myocardial infarction), stroke, congestive heart failure, liver effects, kidney effects, changes in blood cell levels, Stevens Johnson Syndrome (epidermal necrosis and exfoliative dermatitis). It may also cause prolonged bleeding time.
Acute toxicity	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	Based on available data, the classification criteria are not met.
STOT - single exposure	Based on available data, the classification criteria are not met.
STOT - repeated exposure	Based on available data, the classification criteria are not met.
Reproductive toxicity	Based on available data, the classification criteria are not met.
Germ cell mutagenicity	Based on available data, the classification criteria are not met.
Carcinogenicity	Based on available data, the classification criteria are not met.
Aspiration hazard	Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Celecoxib

Rat Oral LD 50 > 2000 mg/kg

Dog Oral LD 50 > 2000 mg/kg

Sodium lauryl sulfate

Rat Oral LD50 1200 mg/kg

Rabbit Dermal LD50 > 2000 mg/kg

Povidone

Rat Oral LD50 100 g/kg

Magnesium Stearate

Rat Oral LD50 > 2000 mg/kg

Rat Inhalation LC50 > 2000 mg/m ^{3}

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Sodium lauryl sulfate	= 1288 mg/kg (Rat)	= 200 mg/kg (Rabbit)	> 3900 mg/m^3 (Rat) 1 h
Povidone	= 100 g/kg (Rat)	-	-

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Celecoxib

Skin irritation Rabbit No effect
Eye irritation Rabbit Minimal
Skin Sensitization - GPMT Guinea Pig No effect

Sodium lauryl sulfate

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild Moderate
Skin Sensitization - GPMT Guinea Pig Negative
Skin Sensitization - LLNA Mouse Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Celecoxib

13 Week(s) Rat Oral 20 mg/kg/day NOAEL Gastrointestinal System, Kidney
13 Week(s) Dog Oral 35 mg/kg/day NOAEL Gastrointestinal system
6 Month(s) Rat Oral 20 mg/kg/day NOAEL Gastrointestinal system, Kidney
12 Month(s) Dog Oral 35 mg/kg/day NOAEL Gastrointestinal system

Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Celecoxib

Reproductive & Fertility-Males Rat Oral 600 mg/kg NOAEL No effects at maximum dose
Embryo / Fetal Development Rat Oral 50 mg/kg/day LOAEL Fetotoxicity
Embryo / Fetal Development Rabbit Oral 100 mg/kg/day LOAEL Fetotoxicity
Embryo / Fetal Development Rat Oral 30 mg/kg/day LOAEL Teratogenic
Embryo / Fetal Development Rabbit Oral 60 mg/kg/day NOAEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Celecoxib

Bacterial Mutagenicity (Ames) *Salmonella* Negative
Mammalian Cell Mutagenicity HGPRT Negative
Direct DNA Interaction Not applicable Negative
In Vitro Cytogenetics Chinese Hamster Ovary (CHO) cells Negative
In Vivo Micronucleus Rat Bone Marrow Negative

Sodium lauryl sulfate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Celecoxib

2 Year(s) Rat Oral 200 (M), 10 (F) mg/kg/day NOAEL Not carcinogenic
2 Year(s) Mouse Oral 25 (M), 50 (F) mg/kg/day NOAEL Not carcinogenic

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Povidone

IARC Group 3 (Not Classifiable)

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided. See Aquatic toxicity data of the active ingredient, below:

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Celecoxib

Daphnia magna (Water Flea) TAD EC50 48 hours > 1.5 mg/L
Pimephales promelas (Fathead Minnow) TAD LC50 96 hours > 1.2 mg/L
Selenastrum capricornutum (Green Alga) TAD NOEC 12 days 0.11 mg/L
Microcystis aeruginosa (Blue-green Alga) TAD NOEC 14 Days 0.089 mg/L

Sodium lauryl sulfate

Cyprinodon variegatus (Sheepshead Minnow) LC50 96 hours 4.1 mg/L
Ceriodaphnia dubia (Daphnids) EC50 48 hours 5.55 mg/L
Desmodesmus subcapitata (Green Alga) ErC50 72 hours > 120 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Celecoxib

Trichoderma viride (Fungus) TAD MIC > 1000 mg/L

Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

Celecoxib

Pimephales promelas (Fathead Minnow) OECD 33 Day(s) NOEC 0.23 mg/L
Daphnia magna (Water Flea) EPA 21 Day(s) NOEC 0.06 mg/L
Ceriodaphnia dubia (Daphnids) TAD 7 Day(s) NOEC 0.17

Sodium lauryl sulfate

Pimephales promelas (Fathead Minnow) 42 Day(s) NOEC => 1.357 mg/L Survival Growth
Ceriodaphnia dubia (Daphnids) 7 Day(s) NOEC 0.88 mg/L Reproduction

12.2. Persistence and degradability

Persistence and degradability

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Celecoxib

Ready 53.2 % After 28 Day(s) Not Ready

Sodium lauryl sulfate

OECD Activated sludge Ready 94-97 % After 28 Day(s) Ready

12.3. Bioaccumulative potential

Bioaccumulation

Partition Coefficient: (Method, pH, Endpoint, Value)

Celecoxib

Measured Log P 3.53

Sodium lauryl sulfate
Measured Log P 0.83

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Sodium lauryl sulfate	The substance is not PBT / vPvB

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects
No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is regulated for transportation as a hazardous material/dangerous good.

UN number: UN 3077
UN proper shipping name: Environmentally Hazardous Substance, Solid, n.o.s (celecoxib)
Transport hazard class(es): 9
Packing group: III
Environmental Hazard(s): Marine Pollutant

5 kg/5L Exception:
UN3082 and UN3077 materials contained in good quality packaging in the quantities listed below are not subject to the dangerous goods transportation regulations by any mode:

* Single packagings containing a net quantity of 5 liters or less for liquids or a net mass of 5 kg or less for solids.
* Combination packagings containing a net quantity per inner packaging of 5 liters or less for liquids or a net mass of 5 kg or less for solids.

Special precautions for user: Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Celecoxib

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4

Lactose NF, monohydrate

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present

Sodium lauryl sulfate

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	205-788-1
AICS	Present

Povidone

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	Not Listed
AICS	Present

Magnesium Stearate

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	209-150-3
AICS	Present

Croscarmellose sodium

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
AICS	Present

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Legend:
TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects

Data Sources:	Pfizer proprietary drug development information. Safety data sheets for individual ingredients.
Reason for revision	Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.
Revision date	06-Dec-2021
Prepared By	Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.